Visser, A. (Arend) (2013) Heeft 6-mercaptopurine een plaats in de behandeling van AML? thesis, Medicine.
![[img]](https://umcg.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
VisserAA.pdf Restricted to Registered users only Download (988kB) |
Abstract
In the past, before azacitidine came available, older and unfit AML patients in the UMCG received palliative treatment with 6-mercaptopurine (6-MP),.In this retrospective, observational cohort study, the treatment with 6-MP was evaluated. The study included all 147 evaluable AML patients who were treated with 6-MP during the last 23 years, i.e. since 1990. The overall response rate defined as a significant and lasting improvement in blood counts was 32%. Median overall survival of responders was 418 days compared to 112 days for nonresponders. Besides newly diagnosed older patients, also patients with refractory or relapsing disease were included. Patients with poor risk cytogenetics and patients with therapy-related AML showed the same response rate as patients with standard risk. We concluded that 6-MP could still have a place in the treatment of AML. It has its value particularly in the treatment of older patients who did not respond to intensive chemotherapy.
| Item Type: | Thesis (Thesis) |
|---|---|
| Supervisor name: | Daenen, Simon |
| Faculty: | Medical Sciences |
| Date Deposited: | 25 Jun 2020 10:53 |
| Last Modified: | 25 Jun 2020 10:53 |
| URI: | https://umcg.studenttheses.ub.rug.nl/id/eprint/1406 |
Actions (login required)
 |
View Item |